Revenue
Cost
Profit
| Item | Category | Value | YoY |
|---|---|---|---|
| Total revenues | revenue | 6.96B | 4.39% |
| Nonoperating income (expense) | revenue | 235.00M | -28.35% |
| Operating income | profit | 2.59B | 15.60% |
| Total costs and expenses | cost | 4.37B | -1.26% |
| Aggregate | revenue | 2.82B | |
| Selling, general and administrative expenses | cost | 1.45B | 15.34% |
| Cost of goods sold | cost | 1.45B | -6.17% |
| Research and development expenses | cost | 1.37B | -0.51% |
| Acquired in-process research and development expenses | cost | 107.00M | -57.71% |
| Income before income taxes | profit | 2.58B | 56.46% |
| Interest expense | cost | 240.00M | -7.69% |
| Net income | profit | 2.02B | 53.69% |
| Income tax expense | cost | 559.00M | 67.37% |
| Segment | Value | YoY |
|---|---|---|
| UNITED STATES | 4.93B | 5.53% |
| Europe | 1.14B | 5.54% |
| Rest Of World | 889.00M | -2.84% |
| Others | 1.00M |
| Segment | Value | YoY |
|---|---|---|
| HIV Products, Biktarvy | 3.36B | 6.70% |
| HIV Products, Descovy | 807.00M | 37.71% |
| Trodelvy | 402.00M | 37.20% |
| Other Products, Yescarta | 332.00M | -13.99% |
| Liver Disease Products, Sofosbuvir/Velpatasvir | 283.00M | -18.21% |
| HIV Products, Genvoya | 264.00M | -27.47% |
| Liver Disease Products, Vemlidy | 237.00M | -5.95% |
| HIV Products, Odefsey | 221.00M | -21.35% |
| HIV Products, Yeztugo | 166.00M | |
| Veklury | 144.00M | -52.32% |
| HIV Products, Symtuza - Revenue Share | 138.00M | 21.05% |
| Other Products, AmBisome | 138.00M | -0.72% |
| Liver Disease Products, Livdelzi | 133.00M | 232.50% |
| Liver Disease Products, Other Liver Disease | 114.00M | -5.79% |
| Cell Therapy Products, Tecartus | 75.00M | -3.85% |
| HIV Products, Other HIV | 73.00M | -19.78% |
| Other Products, Other | 58.00M | -17.14% |
| Royalty, Contract, And Other | 14.00M | -74.07% |
| Item | Category | Value | YoY |
|---|---|---|---|
| Cash, cash equivalent, restricted cash, and restricted cash equivalent, continuing operation | assets | 7.63B | |
| Accounts receivable, net | assets | 4.74B | |
| Prepaid and other current assets | assets | 4.34B | |
| Inventories | assets | 1.91B | |
| Short-term marketable debt securities | assets | 15.00M | |
| Total current assets | assets | 18.64B | |
| Intangible assets, net | assets | 16.38B | |
| Goodwill | assets | 8.31B | |
| Property, plant and equipment, net | assets | 5.64B | |
| Other long-term assets | assets | 4.55B | |
| Deferred tax assets | assets | 1.77B | |
| Long-term marketable debt securities | assets | 983.00M | |
| Total assets | assets | 56.28B | |
| Noncontrolling interest | liabilities | 84.00M | |
| Total stockholders’ equity | liabilities | 23.43B | |
| Long-term debt, net | liabilities | 20.86B | |
| Total current liabilities | liabilities | 9.48B | |
| Other long-term liabilities | liabilities | 1.20B | |
| Long-term income taxes payable | liabilities | 918.00M | |
| Deferred tax liabilities | liabilities | 392.00M | |
| Total gilead stockholders’ equity | equity | 23.52B | |
| Accrued rebates | liabilities | 4.12B | |
| Other current liabilities | liabilities | 3.40B | |
| Current portion of long-term debt, net | liabilities | 1.31B | |
| Accounts payable | liabilities | 645.00M | |
| Retained earnings | equity | 14.13B | |
| Additional paid-in capital | equity | 9.30B | |
| Accumulated other comprehensive income | equity | 78.00M | |
| Common stock, par value $0.001 per share; 5,600 shares authorized; 1,242 and 1,241 shares issued and outstanding, respectively | equity | 1.00M |
| Item | Value |
|---|---|
| Net income | 2.02B |
| Amortization expense | 596.00M |
| Stock-based compensation expense | 218.00M |
| Other noncash income (expense) | 183.00M |
| Deferred income taxes | 179.00M |
| Increase (decrease) in accounts receivable | 134.00M |
| Acquired in-process research and development expenses | 107.00M |
| Depreciation expense | 93.00M |
| Increase (decrease) in prepaid expense and other assets | 5.00M |
| Income tax assets and liabilities, net | -29.00M |
| Increase (decrease) in inventories | -52.00M |
| Accounts payable | -67.00M |
| Increase (decrease) in equity securities, fv-ni | -142.00M |
| Accrued and other liabilities | -702.00M |
| Item | Value |
|---|---|
| Proceeds from sales of marketable debt securities | 2.52B |
| Proceeds from maturities of marketable debt securities | 36.00M |
| Payment for (proceeds from) other investing activity | -17.00M |
| Payments to acquire other investments | -19.00M |
| Payments to acquire businesses, net of cash acquired | -109.00M |
| Payments to acquire property, plant, and equipment | -117.00M |
| Payments to acquire debt securities, available-for-sale | -525.00M |
| Item | Value |
|---|---|
| Proceeds from issuances of common stock | 166.00M |
| Other financing activities, net | -179.00M |
| Payments for repurchase of common stock | -419.00M |
| Payments of dividends | -1.04B |
| Repayments of debt | -2.77B |
| Item | Value |
|---|---|
| Cash and cash equivalents, beginning of period | 7.56B |
| Cash and cash equivalents, end of period | 7.63B |
Instantly decode complex 10-K and 10-Q data. Explore interactive Sankey diagrams for income and balance sheets, and intuitive waterfall charts for cash flows.
Search for a company and select a report on the left panel.
Request Stock Support